WO2002065834A8 - Novel formulations of carvedilol - Google Patents
Novel formulations of carvedilolInfo
- Publication number
- WO2002065834A8 WO2002065834A8 PCT/US2001/050872 US0150872W WO02065834A8 WO 2002065834 A8 WO2002065834 A8 WO 2002065834A8 US 0150872 W US0150872 W US 0150872W WO 02065834 A8 WO02065834 A8 WO 02065834A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carvedilol
- novel formulations
- formulations
- novel
- angina
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01273804A EP1335707A4 (en) | 2000-10-24 | 2001-10-23 | Novel formulations of carvedilol |
US10/415,671 US20040019096A1 (en) | 2001-10-23 | 2001-10-23 | Novel formulations of carvedilol |
AU2001297631A AU2001297631A1 (en) | 2000-10-24 | 2001-10-23 | Novel formulations of carvedilol |
JP2002565411A JP2004518734A (en) | 2000-10-24 | 2001-10-23 | A new formulation of carvedilol |
CA002426811A CA2426811A1 (en) | 2000-10-24 | 2001-10-23 | Novel formulations of carvedilol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24291100P | 2000-10-24 | 2000-10-24 | |
US60/242,911 | 2000-10-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002065834A2 WO2002065834A2 (en) | 2002-08-29 |
WO2002065834A3 WO2002065834A3 (en) | 2002-10-03 |
WO2002065834A8 true WO2002065834A8 (en) | 2003-06-26 |
Family
ID=22916614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/050872 WO2002065834A2 (en) | 2000-10-24 | 2001-10-23 | Novel formulations of carvedilol |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1335707A4 (en) |
JP (1) | JP2004518734A (en) |
AU (1) | AU2001297631A1 (en) |
CA (1) | CA2426811A1 (en) |
WO (1) | WO2002065834A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9023394B2 (en) | 2009-06-24 | 2015-05-05 | Egalet Ltd. | Formulations and methods for the controlled release of active drug substances |
US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3024399A (en) | 1998-04-03 | 1999-10-25 | Bm Research A/S | Controlled release composition |
IN191028B (en) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
EP1929998A3 (en) * | 2001-09-21 | 2008-11-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
WO2004041252A1 (en) | 2002-11-08 | 2004-05-21 | Egalet A/S | Controlled release carvedilol compositions |
DE602004025159D1 (en) | 2003-03-26 | 2010-03-04 | Egalet As | Matrix preparations for the controlled administration of drugs |
JP5072364B2 (en) * | 2003-11-25 | 2012-11-14 | スミスクライン ビーチャム (コーク) リミテッド | Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method |
JP2007512350A (en) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Carvedilol composition treatment and delivery methods |
US7846426B2 (en) | 2005-02-25 | 2010-12-07 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing cardiomyopathy and heart disease |
HU227490B1 (en) * | 2005-08-26 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
CN102218077A (en) | 2006-08-01 | 2011-10-19 | 普里克萨斯医药股份有限公司 | Use of poloxamer for the prevention and/or treatment of heart failure |
HU227881B1 (en) * | 2007-02-23 | 2012-05-29 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
WO2008114276A1 (en) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Novel oral controlled release composition of carvedilol |
US8372387B2 (en) | 2007-04-05 | 2013-02-12 | Phrixus Pharmaceuticals, Inc. | Compositions and methods for the treatment of heart failure |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
FR2936709B1 (en) * | 2008-10-02 | 2012-05-11 | Ethypharm Sa | ALCOHOL-RESISTANT TABLETS. |
TWI415604B (en) * | 2009-09-29 | 2013-11-21 | Tsh Biopharm Corp Ltd | Controlled release carvediolol formulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19637082A1 (en) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Rapidly disintegrating pellets |
HUP0000759A3 (en) * | 1997-03-11 | 2000-11-28 | Darwin Discovery Ltd Cambridge | Dosage forms comprising separate portions of r- and s-enantiomers |
DE19816036A1 (en) * | 1998-04-09 | 1999-10-14 | Roche Diagnostics Gmbh | Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol |
KR100336090B1 (en) * | 1998-06-27 | 2002-05-27 | 윤승원 | Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof |
DE19833119A1 (en) * | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Storage-stable injectable solution of vasodilator and beta blocker Carvedilol contains buffer, organic solvent, antioxidant and complexing agent |
PE20001302A1 (en) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | PREPARATIONS OF A PHARMACEUTICAL COMBINATION CONTAINING CARVEDILOL AND HYDROCHLOROTHIAZIDE |
WO2001035958A1 (en) * | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
CA2402336C (en) * | 2000-04-03 | 2008-03-11 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
-
2001
- 2001-10-23 CA CA002426811A patent/CA2426811A1/en not_active Abandoned
- 2001-10-23 WO PCT/US2001/050872 patent/WO2002065834A2/en not_active Application Discontinuation
- 2001-10-23 JP JP2002565411A patent/JP2004518734A/en active Pending
- 2001-10-23 AU AU2001297631A patent/AU2001297631A1/en not_active Abandoned
- 2001-10-23 EP EP01273804A patent/EP1335707A4/en not_active Withdrawn
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
US9375428B2 (en) | 2003-03-26 | 2016-06-28 | Egalet Ltd. | Morphine controlled release system |
US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9358295B2 (en) | 2009-02-06 | 2016-06-07 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
US9023394B2 (en) | 2009-06-24 | 2015-05-05 | Egalet Ltd. | Formulations and methods for the controlled release of active drug substances |
US9549899B2 (en) | 2012-07-06 | 2017-01-24 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
Also Published As
Publication number | Publication date |
---|---|
EP1335707A4 (en) | 2005-07-06 |
AU2001297631A1 (en) | 2002-09-04 |
AU2001297631A8 (en) | 2005-09-15 |
WO2002065834A2 (en) | 2002-08-29 |
EP1335707A2 (en) | 2003-08-20 |
CA2426811A1 (en) | 2002-08-29 |
WO2002065834A3 (en) | 2002-10-03 |
JP2004518734A (en) | 2004-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002065834A3 (en) | Novel formulations of carvedilol | |
TNSN03083A1 (en) | Mercaptoacetylamide derivatives, a process for their preparation and their use | |
WO2005051322A3 (en) | Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts | |
WO2001079460A3 (en) | Polypeptides having haloperoxidase activity | |
AU2002311012A1 (en) | Endo-beta-1,4-glucanase from bacillus | |
EP1283235A3 (en) | Composition, method of making, and method of using adhesive composition | |
AU2002306918A1 (en) | Methods of modulating angiogenesis | |
WO2003000893A3 (en) | Nucleic acids encoding g protein-coupled receptors | |
WO2003028645A3 (en) | Novel compositions of carvedilol | |
WO2003092622A3 (en) | Carvedilol monocitrate monohydrate | |
AU2002303529A1 (en) | Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene | |
WO2002017858A3 (en) | Role of fosb in bone formation | |
WO2001029032A8 (en) | Process for the preparation of paroxetine | |
WO2003092625A3 (en) | Carvedilol formulations | |
WO2003092626A3 (en) | Carvedilol pharmasolve solvate | |
WO2001074787A3 (en) | Crystalline pharmaceutical | |
AU2002351560A1 (en) | Treatment of congestive heart failure | |
WO2003005970A3 (en) | Carvedilol polymorph | |
NO20034412L (en) | Mercaptoacetylamide derivatives, process for their preparation and use | |
AU2003214299A1 (en) | Hiv-1 virus tat-protein mutants | |
WO2003039474A3 (en) | Method and composition for the modulation of angiogenesis | |
AU2002245505A1 (en) | Non-racemic hexafluoreleucine, and methods of making and using it | |
AUPQ680900A0 (en) | Method of modifying hardwood traits | |
AU2002341883A1 (en) | 3-(heteroarylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors | |
AU2002336603A1 (en) | 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2426811 Country of ref document: CA Ref document number: 10415671 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002565411 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001273804 Country of ref document: EP |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 35/2002 UNDER (22) REPLACE "19 OCTOBER 2001 (19.10.2001)" BY "23 OCTOBER 2001 (23.10.2001) |
|
WWP | Wipo information: published in national office |
Ref document number: 2001273804 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001273804 Country of ref document: EP |